首页> 外文期刊>Virology Journal >Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study
【24h】

Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study

机译:江苏省冠病毒疾病患者临床和病毒学课程,中国:回顾性,多中心队列研究

获取原文
       

摘要

The clinical and virological course of patients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to describe the clinical and virological characteristics of COVID-19 patients from 10 designated hospitals in 10 cities of Jiangsu province, China. The factors associated with the clearance of SARS-CoV-2 were investigated. A total of 328 hospitalized patients with COVID-19 were retrospectively recruited. The epidemiological, clinical, laboratory, radiology and treatment data were collected. The associated factors of SARS-CoV-2 clearance were analyzed. The median duration of hospitalization was 16.0?days (interquartile range [IQR] 13.0–21.0?days). On multivariate Cox regression analysis, age??60?years (hazard ratio [HR] 0.643, 95% confidence interval [CI] 0.454–0.911, P?=?0.013) was associated with the delayed SARS-CoV-2 clearance, while the atomized inhalation of interferon α-2b could improve the clearance of SARS-CoV-2 (HR, 1.357, 95% CI 1.050–1.755, P?=?0.020). Twenty-six (7.9%) patients developed respiratory failure and 4 (1.2%) patients developed ARDS. Twenty (6.1%) patients were admitted to the ICU, while no patient was deceased. Our study found that age??60?years was associated with the delayed SARS-CoV-2 clearance, while treated with atomized inhalation of interferon α-2b could promote the clearance of SARS-CoV-2.
机译:缺乏冠状病毒疾病(Covid-19)患者的临床和病毒学过程。我们的旨在描述中国江苏省10个城市10个指定医院的Covid-19患者的临床和病毒学特征。研究了与SARS-COV-2的间隙相关的因素。回顾性招募了328名住院治疗的Covid-19患者。收集流行病学,临床,实验室,放射学和治疗数据。分析了SARS-COV-2间隙的相关因素。住院中位数的中位数为16.0?天(四分位数[IQR] 13.0-21.0?天)。在多元COX回归分析中,年龄?&?60?岁(危害比[HR] 0.643,95%置信区间[CI] 0.454-0.911,P?= 0.013)与延迟的SARS-COV-2间隙有关,而干扰素α-2b的雾化吸入可以改善SARS-COV-2的间隙(HR,1.357,95%CI 1.050-1.755,P?= 0.020)。二十六(7.9%)患者发育呼吸衰竭,4名(1.2%)患者开发了ARDS。患有二十(6.1%)的患者被录取到ICU,同时没有死亡的患者。我们的研究发现,年龄?&?60?岁月与延迟的SARS-COV-2间隙有关,同时用干扰素α-2b的雾化吸入治疗,可以促进SARS-COV-2的间隙。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号